**Contents**

**More information and contact:** ........................................................................................................ 2

**National calls: NWO / ZonMw calls** .................................................................................................. 2
  - NWO Open Technology Programme 2022 ..................................................................................... 2
  - NWO Open Competition Domain Science - M ............................................................................... 2
  - NWO-ReumaNL KIC call: 'Early detection of osteoarthritis Innovations for detection and diagnosis'. 2
  - ZonMw Onderzoek naar besmetting en verspreiding van COVID-19: open ronde ....................... 2
  - ZonMw Verwacht in 2022/2023 .................................................................................................... 2

**International calls: HE, IHI, Cancer Mission** .................................................................................. 2
  - Horizon Europe: Cluster 1 Health (examples) .................................................................................. 2
  - Horizon Europe: Cluster 4 Digital, Industry, Space (examples): ....................................................... 3
  - European Innovation Council (EIC): .............................................................................................. 3
  - Innovative Health Initiative (IHI): .................................................................................................. 4
  - JPIAMR AMR diagnostics and surveillance 2023 ......................................................................... 4
  - Horizon Europe Cancer Mission .................................................................................................... 5

**Foundations** ..................................................................................................................................... 5
  - KWF .............................................................................................................................................. 5
  - ATTRACT ...................................................................................................................................... 5
  - KWF Call PPS 2023-1: Publiek-Private Samenwerkingen ................................................................. 6
  - KWF CALL 2023-3 / ONTWIKKELING & IMPLEMENTATIE ......................................................... 6
  - Hanarth Fonds Artificial Intelligence in Oncology ............................................................................ 7
  - Central Auditory Process Disorders Grant Opportunity ..................................................................... 7
  - Alzheimer Nederland ...................................................................................................................... 7

**Industrial funding** ............................................................................................................................. 8
  - Asahi Kasei Pharma Corporation – deadline 28.02.2023 ................................................................. 8
More information and contact:
If you are interested in applying to opportunities mentioned here or if you are already working on a research proposal, contact me! We can discuss your ideas, consortium and call requirements. Together we can make sure your proposal aligns well with call objectives.

Your funding advisor and TU Delft Health coordinator: Jaga Schreiber, j.k.schreiber@tudelft.nl

National calls: NWO / ZonMw calls
NWO Emerging Key Enabling Technologies – deadline pre-proposal 20.12.2022
NWO Open Technology Programme 2022
NWO Open Competition Domain Science - M
NWO NWA Open Mind 2023 – deadline 14.04.2023
NWO Safe and healthy food and food systems - deadline pre-proposal 17.01.2023
NWO-ReumaNI KIC call: 'Early detection of osteoarthritis Innovations for detection and diagnosis' (not yet published) - deadline pre-proposal 14.02.2023 (full proposal 20.06.2022)

ZonMw Onderzoek naar besmetting en verspreiding van COVID-19: open ronde – deadline 01.12.2022
Deze subsidieronde beoogt nieuwe kennis over besmetting en verspreiding van SARS-CoV-2 te genereren, ter identificering en onderbouwing van maatregelen en beleid met betrekking tot:
-het voorkomen of uitstellen van COVID-19 besmetting,
-het voorkomen van virusverspreiding in risicogroepen,
-en de beheersing in de populatie om de pandemie te beperken.
In geval van uitblijven van een volgende golf van COVID-19 moet de gegenereerde kennis van toepassing zijn op andere infectieziekten en/of bijdragen aan pandemische paraatheid.

ZonMw Verwacht in 2022/2023: Innovatieve ideeën voor preventie & gezondheidsbevordering
Dit jaar wordt subsidie beschikbaar gesteld voor het indienen van voorstellen die nieuwe inzichten en onverwachte doorbraken in preventie- en gezondheidsbevorderings-onderzoek teweegbrengen. We nodigen uit tot het indienen van “out of the box” onderzoeksprojectplannen, met een korte looptijd (9-18 maanden) en een beperkt budget. De projecten moeten in potentie waarde hebben voor het bevorderen van de inzet van preventie in ons gezondheids-systeem en/of het verbeteren van de fysieke of mentale publieke gezondheid, waarbij het uitgangspunt de brede benadering van gezondheid is. Er mag gebruik gemaakt worden van vernieuwende onderzoeks- en participatiemethoden.

International calls: HE, IHI, Cancer Mission
Horizon Europe: Cluster 1 Health (examples)

<table>
<thead>
<tr>
<th>DHI pillar</th>
<th>NeuroTech</th>
<th>OncoTech</th>
<th>CardioTech</th>
<th>Integrated Tech.</th>
</tr>
</thead>
</table>

The role of environmental pollution in non-communicable diseases: air, noise and light and hazardous waste pollution (RIA; 60 mln: 7-8 mln, 8 projects)

Interventions in city environments to reduce risk of non-communicable disease (LMICs) (RIA; 20 mln: 3-4 mln, 5 projects)
Validation of fluid-derived biomarkers for the prediction and prevention of brain disorders (RIA; 25 mln: 6-8 mln, 3 projects)

Environmentally sustainable and climate neutral health and care systems (RIA; 20 mln: 4-6 mln, 4 projects)

Integrated, multi-scale computational models of patient patho-physiology (‘virtual twins’) for personalised disease management (RIA, 50 mln: 8-10 mln, 5 projects)

Harnessing the potential of real-time data analysis and secure Point-of-Care computing for the benefit of person-centred health and care (IA, 35 mln: 8-10 mln, 4 projects)

Innovative non-animal human-based tools and strategies for biomedical research (RIA, 25mln, 4-6 mln, 4 projects)

Bio-printing of living cells for regenerative medicine (RIA, 25 mln: 6-8 mln, 4 projects)

**Horizon Europe: Cluster 4 Digital, Industry, Space** (examples):

<table>
<thead>
<tr>
<th>DHI pillar</th>
<th>NeuroTech</th>
<th>OncoTech</th>
<th>CardioTech</th>
<th>Integrated Tech.</th>
</tr>
</thead>
<tbody>
<tr>
<td>HORIZON-CL4-2023-DIGITAL-EMERGING-01-53: Versatile light sources and systems as tools for manufacturing and medical application (Photonics Partnership) (RIA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HORIZON-CL4-2024-RESILIENCE-01-36: Advanced biomaterials for the Health Care (IA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HORIZON-CL4-2023-RESILIENCE-01-33: Smart sensors for the Electronic Appliances market (RIA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HORIZON-CL4-2023-DIGITAL-EMERGING-01-57: Advanced imaging and sensing technologies (IA)(Photonics Partnership)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HORIZON-CL3-2023-DRS-01-01: Improving social and societal preparedness for disaster response and health emergencies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HORIZON-CL2-2023-TRANSFORMATIONS-01-08: Integrated care solutions leading to better quality, person-centred long-term care and overcoming territorial inequalities in their provision</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**European Innovation Council (EIC):**

<table>
<thead>
<tr>
<th>DHI pillar</th>
<th>NeuroTech</th>
<th>OncoTech</th>
<th>CardioTech</th>
<th>Integrated Tech.</th>
</tr>
</thead>
<tbody>
<tr>
<td>With its Pathfinder programme the EIC supports the exploration of bold ideas for radically new technologies. It welcomes the high-risk / high gain and interdisciplinary cutting-edge science collaborations that underpin technological breakthroughs.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Pathfinder goes beyond what is already known. Visionary thinking can open up promising avenues towards powerful new technologies. Applicants participating in EIC Pathfinder projects are typically visionary scientists and entrepreneurial researchers from universities, research organisations, start-ups, high-tech SMEs or industrial stakeholders interested in technological research and innovation.

**EIC Pathfinder Open** (TRL 1-4) – not yet published, expected for March-May 2023

EIC Pathfinder Challenge 2023 (drafts: Precision Nutrition, Disease modelling and gene expression in space, Defeating blindness with autonomous robots for nerve re engineering) - not yet published, expected for October 2023
Innovative Health Initiative (IHI) -

The Innovative Health Initiative (IHI) is a public-private partnership (PPP) between the European Union and the European life science industries. Our core goals are to translate health research and innovation into tangible benefits for patients and society, and ensure that Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health research.

<table>
<thead>
<tr>
<th>DHI pillar</th>
<th>NeuroTech</th>
<th>OncoTech</th>
<th>CardioTech</th>
<th>Integrated Tech.</th>
</tr>
</thead>
</table>

IHI call 3 (single stage call)

**Topic 1:** Screening platform and biomarkers for prediction and prevention of diseases of unmet public health need

**Topic 2:** Patient generated evidence to improve outcomes, support decision making, and accelerate innovation

**Topic 3:** Combining hospital interventional approaches to improve patient outcomes and increase hospital efficiencies

**Topic 4:** Strengthening the European ecosystem for Advanced Therapy Medicinal Products (ATMPs) and other innovative therapeutic modalities for rare diseases

**Topic 5:** Digital health technologies for the prevention and personalised management of mental disorders and their long-term health consequences

IHI call 4 (two stage call)

**Topic 1:** Expanding translational knowledge in minipigs: a path to reduce and replace non-human primates in non-clinical drug safety assessment

**Topic 2:** Patient-centric blood sample collection to enable decentralised clinical trials and improve access to healthcare

Get informed! If you are considering applying for an IHI call for proposals, we strongly encourage you to read the call documents, and in particular the guide for applicants.

Sign up for the IHI Call Days [https://ihi-call-days.ihi.b2match.io/home](https://ihi-call-days.ihi.b2match.io/home)

Registration is now open for the IHI Call Days on call 3 (12-15 December 2022) and call 4 (18-19 January 2023). The Call Days include info sessions on the topics and our rules and procedures, pitching sessions (for call 3), and access to a brokerage platform to meet potential project partners.

JPIAMR AMR diagnostics and surveillance 2023 - Deadline pre-proposals 07.03.2023

<table>
<thead>
<tr>
<th>DHI pillar</th>
<th>NeuroTech</th>
<th>OncoTech</th>
<th>CardioTech</th>
<th>Other</th>
</tr>
</thead>
</table>

Pre-announcement: JPIAMR will launch in 2023 an international call for projects under the umbrella of JPIAMR and within the framework of the ERA-NET JPIAMR-ACTION. The call Development of innovative strategies, tools, technologies, and methods for diagnostics and surveillance of antimicrobial resistance will involve 21 funders from 18 countries. The total estimated call budget is about 18,8 million Euro. Proposals should aim to address unmet needs in the AMR diagnostics and surveillance sectors beyond the current state of the art, by focusing on one of the topics of the call:
Topic 1: To develop novel, or improve existing, diagnostics, including point of care diagnostics, that can rule out antimicrobial use or help identify the most effective antimicrobial treatment.

Topic 2: To develop or improve existing strategies, technologies or methods, or data use strategies to support One Health AMR surveillance.

Horizon Europe Cancer Mission – not yet published, opening: 12 Jan 2023 ; Deadline(s): 12 Apr 2023

<table>
<thead>
<tr>
<th>DHI pillar</th>
<th>NeuroTech</th>
<th>OncoTech</th>
<th>CardioTech</th>
<th>Integrated Tech.</th>
</tr>
</thead>
<tbody>
<tr>
<td>HORIZON-MISS-2023-CANCER-01-01: Addressing poorly-understood tumour-host interactions to enhance immune system-centred treatment and care interventions in childhood, adolescent, adult and elderly cancer patients. (7-12 mln / total budget ca. 37 mln, RIA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HORIZON-MISS-2023-CANCER-01-02: Enhance primary cancer prevention through sustainable behavioural change (4-6 mln / total budget 25 mln, RIA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HORIZON-MISS-2023-CANCER-01-03: Pragmatic clinical trials on minimally invasive diagnostics (6-8 mln / total budget 43 mln, RIA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HORIZON-MISS-2023-CANCER-01-04: Establish best practices and tools to improve the quality of life for childhood cancer patients, survivors and their families in European regions (6 mln / total budget 6 mln, IA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Foundations

KWF Call for advancement of biomarkers to daily practice - deadline 13.12.2022

<table>
<thead>
<tr>
<th>DHI pillar</th>
<th>NeuroTech</th>
<th>OncoTech</th>
<th>CardioTech</th>
<th>Integrated Tech.</th>
</tr>
</thead>
<tbody>
<tr>
<td>To validate (combinations of) already discovered, promising biomarkers that correlate with patient relevant outcomes or treatment responses and that can be used in daily clinical practice in the near future. Therefore, efforts are needed to set up collaborative, multidisciplinary studies with special attention to (combinations of) biomarkers that are potential candidates for clinical implementation. The focus of this call is to bring together the necessary expertise in the field of biomarker research and clinical care to reach the next developmental phase of the biomarker candidate(s) on their way to daily practice and to provide the appropriate framework and funding. <a href="#">LINK</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ATTRACT International call for research proposals on rare cancer drug development ATTRACT - deadline pre-proposal 31.01.2023

<table>
<thead>
<tr>
<th>DHI pillar</th>
<th>NeuroTech</th>
<th>OncoTech</th>
<th>CardioTech</th>
<th>Integrated Tech.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Five European anti-cancer charities are joining forces to stimulate international research on rare cancer drug development. The focus of this joint international call, the ATTRACT-Call, is on late phase (2/3) clinical trials on rare cancer drugs. Main goals are improving treatment for rare cancer patients and accelerate the development of drugs for rare cancers. We encourage researchers and clinicians from different countries to join forces, share knowledge, and collaborate. Eligible for this call are multicenter, international phase 2/3 clinical trials on medicinal products for rare cancer treatment (including drug repurposing). Main applicants as well as research consortium partners should be located in one of the funding countries (Belgium, France, the Netherlands, Spain), with a minimum of 2 participating countries. Applicants (funding recipients) should be either Academic</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

[LINK](#)
research groups or Clinical/Public health sector research groups. To support swift enrolment of study patients in clinical trials, inclusion centers outside of the funding countries may be included in the proposal. Public-private collaborations are accepted under strict conditions; note that private parties will not receive direct funding. Active patient participation in the set up and execution of the proposals is required. A strong regulatory and implementation strategy (incl. EMA advise, orphan designation, early HTA) is not obliged but highly recommended.

The ATTRACT consortium is hosting two Question & Answer sessions for applicants prior to closing of the pre-proposal, to answer any questions regarding the application. These are scheduled on December 1st 2022 and January 9th 2023. Please register for (one of) the webinars. Register here

KWF Call PPS 2023-1: Publiek-Private Samenwerkingen – deadline 14.02.2023

<table>
<thead>
<tr>
<th>DHI pillar</th>
<th>NeuroTech</th>
<th>OncoTech</th>
<th>CardioTech</th>
<th>Integrated Tech.</th>
</tr>
</thead>
</table>

Scientists employed by a Dutch knowledge institute can submit a proposal. There needs to be a genuine collaboration with at least one private for-profit partner contributing to the project. The research proposal fits within the Knowledge and Innovation Agenda 2020-2023, (https://www.health-holland.com/sites/default/files/downloads/kennisen-innovatieagenda-2020-2023-gezondheid-en-zorg.pdf) See pages 17-35 of the KIA for the mission of the PPP-program.

• The project consists of at least one private, for-profit partner and one Dutch knowledge institute.
• The project will be realized at joint cost and risk and all consortium partners will make a substantial contribution to the project, not only in cash or but also in kind. In other words, the project should be a true collaborative effort.
• The percentage of the project costs which can be financed from the grant depends on the type of research performed as follows:
  o Fundamental research up to 75%
  o Industrial research up to 50%
  o Experimental development up to 25%

More information HERE

KWF CALL 2023-3 / ONTWIKKELING & IMPLEMENTATIE - deadline 21.03.2023

<table>
<thead>
<tr>
<th>DHI pillar</th>
<th>NeuroTech</th>
<th>OncoTech</th>
<th>CardioTech</th>
<th>Integrated Tech.</th>
</tr>
</thead>
</table>

KWF offers various funding types:
• Research projects
• Young Investigator Grants
• Unique High Risk projects
• Consortium projects
• Infrastructure initiatives
• Implementation Funding

After choosing a funding type, you need to select a research phase. KWF identifies seven research phases. When you apply within the open call you have to take the research phase into account since this is the basis on which projects are divided between the two open call committees: Exploration and Development & Implementation. The exploration track focuses on finding solutions to address knowledge gaps, obtaining new scientific knowledge and identifying first leads and targets. The Development & Implementation track focuses on the development and implementation of leads and targets in the area of prevention, diagnosis, treatment and coping with cancer. The focus is on problems relevant to patients or the general public in a healthcare or practical setting.

More information HERE
Hanarth Fonds Artificial Intelligence in Oncology – deadline anticipated for March 2023

<table>
<thead>
<tr>
<th>DHI pillar</th>
<th>NeuroTech</th>
<th>OncoTech</th>
<th>CardioTech</th>
<th>Integrated Tech.</th>
</tr>
</thead>
</table>

The Hanarth Fonds makes funding available for research and education in artificial intelligence and machine learning within oncology, with a special focus on rare cancers in adults. The fund deals with two types of financing:
Research projects in the aforementioned research area in which algorithms in the field of artificial intelligence are developed and/or applied to data sets;
A fellowship to attend a specific training trajectory which recognizes the added value of incorporating machine learning into research, daily clinical work and organization.
This website will give you more information on the fund, the organization and the possibilities, conditions and procedure of funding. You can also apply for funding on this website.

Central Auditory Process Disorders Grant Opportunity – Letters of Intent due January 4, 2023

<table>
<thead>
<tr>
<th>DHI pillar</th>
<th>NeuroTech</th>
<th>OncoTech</th>
<th>CardioTech</th>
<th>Integrated Tech.</th>
</tr>
</thead>
</table>

Autism Speaks, with generous support from the Royal Arch Research Assistance, is funding one pilot research award, one predoctoral fellowship award and one postdoctoral fellowship focused on understanding, evaluating and/or treating individuals with central auditory processing disorder (CAPD), particularly as it relates to autism spectrum disorder (ASD).

The pilot study will be funded at $60,000 for one year, the predoctoral fellowship will be awarded $40,000 per year for two years and the postdoctoral fellowship will be awarded $55,000 a year for two years. Please see the RFA for more information and application instructions.

2022 Predoctoral and Postdoctoral Fellowships – release planned for December 2022
The primary purpose of our predoctoral and postdoctoral fellowships is to provide highly qualified candidates with exceptional research training opportunities broadly related to the study of ASD.

Alzheimer Nederland

<table>
<thead>
<tr>
<th>DHI pillar</th>
<th>NeuroTech</th>
<th>OncoTech</th>
<th>CardioTech</th>
<th>Integrated Tech.</th>
</tr>
</thead>
</table>

Alzheimer Nederland heeft diverse subsidievormen om onderzoek naar dementie te bevorderen. Hieronder vind je een overzicht van de verschillende financieringsvormen.

Young Outstanding Researcher Award open, deadline: 12 januari 2023
Asahi Kasei Pharma Corporation – deadline 28.02.2023

Asahi Kasei Pharma Corporation will offer selected candidates collaborative research opportunities, with research funding and contribution to the program through our scientists’ research activities.

If the program achieves progress, we will consider a separate license agreement that includes payments such as upfront, milestones, and royalties.

Drug discovery platform technology
Autoimmune disease
Renal disease
Neurodegenerative disease
Bone disease
Pain